Objective: China’s new patented medicine policies could be improved with international drug pricing experience. Methods is key person interviews and literature review. Results and suggestions: Scientific pricing methods have been employed in many countries’ patented medicine pricing, which mainly include health technology assessment (HTA), external reference pricing (ERP), internal reference price, cost based pricing, as well as some purchasing policies. China’s Patented medicine policies are supposed to be related to health insurance policy. Currently, ERP could be applied to patented medicine negotiation policy, while HTA system should be established gradually.